CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its Helicon™ peptide platform, and ARTBIO, Inc. (“ARTBIO”), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), announced a collaboration to co-develop Helicon-enabled ARTs (HEARTs) to transform outcomes for patients with multiple types of cancer..

马萨诸塞州剑桥市（商业新闻短讯）--FogPharma®是一家临床阶段的生物制药公司，致力于使用其Helicon™肽平台提供一类新的治疗方法，超越了目前可用药物的限制，而ARTBIO，Inc.（“ARTBIO”）是一家临床阶段的放射性制药公司，开发了一类新的212Pbα放射性配体疗法（ARTs），宣布合作开发具有螺旋功能的ARTs（HEARTs），以改变多种癌症患者的预后。。

ARTBIO and FogPharma will co-develop novel HEARTs against multiple targets, leveraging FogPharma’s field-leading Helicon platform of tunable stabilized α-helical peptides and ARTBIO’s AlphaDirect™ platform for the development of ARTs using the best-in-class isotope, 212Pb. ARTs with 212Pb have the ideal clinical profile due to a short half-life that delivers maximal energy into tumors with high stability and the ability to image with SPECT/CT.

ARTBIO和FogPharma将共同开发针对多个靶标的新型心脏，利用FogPharma的可调稳定α-螺旋肽领域领先的Helicon平台和ARTBIO的AlphaDirect™平台，使用同类最佳同位素212Pb开发ART。212Pb的ART具有理想的临床特征，因为半衰期短，可以为肿瘤提供最大的能量，具有高稳定性和SPECT/CT成像能力。

The synergy of these two powerful platforms offers promising potential to create next-generation ARTs with properties ideal for precise delivery to tumors..

这两个强大平台的协同作用为创建具有理想特性的下一代ART提供了有希望的潜力，这些特性非常适合精确递送至肿瘤。。

“Our AI-enabled Helicon platform provides an unprecedented level of chemical flexibility and diversity for modifying the crucial chemical and biological properties of peptides, a capability that we have leveraged to address previously undruggable protein:protein interactions inside the cell. We are thrilled to begin our collaboration with ARTBIO, wherein we extend the use of our Helicons to bind extracellular proteins and use our Helicons to finely tune distribution and elimination properties, paving the way for a new safe and effective category of targeted radioligand therapy,” stated Mathai Mammen, M.D., Ph.D., CEO of FogPharma.

FogPharma首席执行官Mathai Mammen医学博士表示：“我们支持人工智能的Helicon平台为修饰肽的关键化学和生物学特性提供了前所未有的化学灵活性和多样性，我们利用这一能力来解决以前不可治疗的蛋白质：细胞内的蛋白质相互作用。我们很高兴开始与ARTBIO的合作，其中我们扩展了螺旋的使用范围，以结合细胞外蛋白质，并使用螺旋来微调分布和消除特性，为新的安全有效的靶向放射性配体治疗类别铺平了道路。”。

“Our aim is to revolutionize outcomes for cancer patients in critical need.”.

“我们的目标是彻底改变急需癌症患者的预后。”。

“Alpha radioligand therapy, and 212Pb in particular, has shown tremendous promise as a new class of radiopharmaceuticals. This collaboration with FogPharma enables ARTBIO to advance next-generation therapeutics specifically designed to treat solid tumors,” said Emanuele Ostuni, Ph.D., CEO of ARTBIO.

ARTBIO首席执行官Emanuele Ostuni博士说：“α-放射性配体疗法，特别是212Pb，作为一类新的放射性药物显示出巨大的前景。与FogPharma的合作使ARTBIO能够推进专门设计用于治疗实体瘤的下一代治疗剂。”。

“FogPharma has a shared vision of radically changing the current treatment paradigms for cancers, and together we will fuse science, technology, and collective passion to improve patient outcomes.”.

“FogPharma有一个共同的愿景，即从根本上改变目前的癌症治疗模式，我们将共同融合科学、技术和集体热情，以改善患者的预后。”。

The partners will contribute equally to the collaboration across research, development and commercialization phases; additional financial terms are undisclosed.

合作伙伴将为研究、开发和商业化阶段的合作做出同等贡献；其他财务条款未披露。

About FogPharma®

关于FogPharma®

FogPharma is a biopharmaceutical company pioneering the discovery and development of Helicon™ therapeutics, which are peptides capable of efficient cell entry and modulation of both protein-protein and protein-DNA interactions. Through Helicon therapeutics, FogPharma is poised to revolutionize the medical possibilities for patients by precisely drugging intracellular targets long understood to be significant drivers of disease but never before drugged due to the limitations of existing drug modalities to act within the cell.

FogPharma是一家生物制药公司，开创了Helicon™治疗剂的发现和开发，Helicon™治疗剂是一种能够有效进入细胞并调节蛋白质-蛋白质和蛋白质-DNA相互作用的肽。通过Helicon therapeutics，FogPharma准备通过精确地对细胞内靶标进行药物治疗，从而彻底改变患者的医疗可能性。长期以来，细胞内靶标被认为是疾病的重要驱动因素，但由于现有药物在细胞内的作用方式的局限性，以前从未进行过药物治疗。

FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor, is being evaluated in a Phase 1/2 study for patients with advanced solid tumors, including colorectal cancer. FogPharma is fully leveraging the unprecedented potential Helicons present by deploying proprietary, custom-built machine learning and computational methods as part of its discovery and development process.

FOG-001是该公司第一种TCF阻断β-连环蛋白抑制剂，正在一项针对包括结直肠癌在内的晚期实体瘤患者的1/2期研究中进行评估。作为其发现和开发过程的一部分，FogPharma通过部署专有的定制机器学习和计算方法，充分利用了前所未有的潜在螺旋。

FogPharma has raised more than $500 million to date from leading life sciences investors. FogPharma is headquartered in Cambridge, Mass. For more information, please visit: www.fogpharma.com..

福格制药（FogPharma）迄今已从领先的生命科学投资者那里筹集了5亿多美元。FogPharma总部位于马萨诸塞州剑桥。有关更多信息，请访问：www.FogPharma.com。。

About ARTBIO

关于ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb212) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety.

ARTBIO是一家临床阶段的放射性制药公司，通过创建一类新的α放射性配体疗法（ARTs）来重新定义癌症治疗。独特的ARTBIO方法选择最佳的α前体同位素（Pb212）和肿瘤特异性靶标，以产生具有最高疗效和安全性潜力的治疗剂。

The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital.

该公司的AlphaDirect™技术是同类212Pb隔离方法中的首创，它为可靠的ART生产和交付提供了分布式制造方法。ARTBIO正在推进多项管道项目，领先项目AB001目前正在进行首次人体试验。ARTBIO是由奥斯陆大学和挪威镭医院在放射治疗方面进行了近一个世纪的开创性工作而形成的长期科学遗产。